Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Jun;31(6):3894-3905.
doi: 10.1245/s10434-024-15121-2. Epub 2024 Mar 17.

Efficacy Assessment of Post-nephrectomy Adjuvant Therapies in Patients with Renal Cell Carcinoma

Kaiyue Ding #  1   2 , Zhixuan Yang #  1   2 , Danyan Zhang  1   2 , Lin Sun  3   4
Affiliations
Meta-Analysis

Efficacy Assessment of Post-nephrectomy Adjuvant Therapies in Patients with Renal Cell Carcinoma

Kaiyue Ding et al. Ann Surg Oncol. 2024 Jun.

Abstract

Objective: The objective of our study was to integrate the efficacy results of post-nephrectomy adjuvant therapies in renal cell carcinoma (RCC) patients with risk of recurrence, and attempt to determine the optimal intervention choice.

Methods: We performed standard meta-analysis procedures in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The PubMed, Embase, and Cochrane Library databases were searched from inception to 22 September 2022. Randomized controlled trials reporting overall survival (OS) or disease-free survival (DFS) of adjuvant therapies, including immune checkpoint inhibitors (ICIs) and targeted therapies, in adult post-nephrectomy RCC patients were eligible for inclusion.

Results: Seven studies involving 7548 participants were included in our analyses. In contrast with placebo, DFS benefit with ICIs was only observed in female RCC patients and RCC patients with high programmed death-ligand 1 (PD-L1) expression (≥ 1%), sarcomatoid features, and M0 intermediate-high risk. Network meta-analyses demonstrated that pembrolizumab exhibited both DFS and OS benefit compared with placebo, sunitinib, sorafenib, and girentuximab, and only DFS benefit compared with atezolizumab and nivolumab plus ipilimumab.

Conclusions: Our results suggest that post-nephrectomy RCC patients with sarcomatoid differentiation and high PD-L1 expression were more responsive to ICIs. Furthermore, pembrolizumab monotherapy exhibited superior DFS and OS results over other adjuvant therapies.

Keywords: Disease-free survival; Overall survival; Post-nephrectomy adjuvant therapy; Randomized controlled trial; Renal cell carcinoma; Subgroup analysis.

PubMed Disclaimer

References

    1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660 . - DOI - PubMed
    1. Motzer RJ, Jonasch E, Agarwal N, et al. Kidney cancer, version 32022, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2022;20(1):71–90. https://doi.org/10.6004/jnccn.2022.0001 . - DOI
    1. International Agency for Research on Cancer (World Health Organization). Kidney—Source: Globocan 2022. https://gco.iarc.fr/today/data/factsheets/cancers/29-Kidney-fact-sheet.pdf . Accessed 3 Sep 2023.
    1. Capitanio U, Bensalah K, Bex A, et al. Epidemiology of renal cell carcinoma. Eur Urol. 2019;75(1):74–84. https://doi.org/10.1016/j.eururo.2018.08.036 . - DOI - PubMed
    1. Crocerossa F, Carbonara U, Cantiello F, et al. Robot-assisted radical nephrectomy: a systematic review and meta-analysis of comparative studies. Eur Urol. 2021;80(4):428–39. https://doi.org/10.1016/j.eururo.2020.10.034 . - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources